Sign In
Buy DRUG
$73.26
-1.37 (-1.84%)
At Close: Jul 31, 2026
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Bioscience
Why did this penny stock skyrocket 1,500% in a day
09:05am, Wednesday, 16'th Oct 2024
When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a meteoric rise, with minimal fundamental factors supporting th
Bright Minds Biosciences Stock Surges Almost 1,500%
08:46am, Wednesday, 16'th Oct 2024
Bright Minds Biosciences NASDAQ: DRUG, a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading unde
Canadian psychedelics company Bright Minds shares rise 1,446% in one day
08:04am, Wednesday, 16'th Oct 2024
Yesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of psychedelics, saw its shares rocket by a frankly psychedelic-looking 1,445.8% to $38.49 from $2.50 at the s
Bright Minds is Unaware of Any Material Changes
09:09pm, Tuesday, 15'th Oct 2024
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
09:00am, Thursday, 03'rd Oct 2024
Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnerin
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
10:00am, Thursday, 19'th Sep 2024
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on Septem
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
08:05am, Tuesday, 25'th Jun 2024
FDA confirms the favorable benefit-risk profile of WAKIX Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product
PLYMOUTH MEETING, Pa. , June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Applica
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
08:10am, Tuesday, 11'th Jun 2024
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug D
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
06:50am, Thursday, 20'th Jul 2023
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
10:33am, Wednesday, 12'th Jul 2023
Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-cons
Bright Minds Announces Effective Date of Share Consolidation
06:50am, Tuesday, 11'th Jul 2023
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on de
